Jobs
View more job listings or post a job
Gate Bioscience Director of Toxicology
Nura Bio Director of Toxicology
Nura Bio Vice President of CMC
MilliporeSigma Emerging Biotech Market Development Manager - San Fransisco
How Cancer LLC Social Media Digital Marketing Specialist  
How Cancer LLC Syndicated National Writer - Cancer 
University of California, Davis SCREENING SUPERVISOR
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Post a job

Symposium

[Free Online] The Science and Stories of Promising Biotech Startups


Speakers: Catherine Sabatos-Peyton, Larkspur Bioscience; Cyriac Roeding, Earli; Yonglei Shang, Amberstone Biosciences; Brad Niles, ARIZ Precision Medicine
Organizers: Toby Freedman (Synapsis Search); Donald McCarthy (Dawn Biopharma); Shichang Miao (PBSS); Lu Lu (MicuRx Pharmaceuticals)
Date: 2025-02-13
Time: 8:30-13:00 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2025-02-12  (it will close sooner if the seating cap is reached)

About the Topic

This symposium series aims to provide a platform for promising biotech startup companies to highlight their science and share their stories in building a fledgling business.

Time (PT) Topic Speaker
8:30-8:40 am PBSS Welcome Shichang Miao, PhD, PBSS
8:40-9:15 am Target Cancer Cell Fitness: a Novel Approach to Exposing Cancer Vulnerabilities Catherine Sabatos-Peyton, PhD, CEO, Larkspur Biosciences
9:15-9:50 am Turning Cancer Against Itself: Reprogramming Cancer to Reveal, and Ultimately, Kill Itself Cyriac Roeding, Co-founder & CEO, Earli
9:50-10:25 am PRDM2 as a Druggable Target in Lung Cancer Brad Niles, PhD, CEO, ARIZ Precision Medicine
10:25-10:35 am Break -
10:35-11:10 am Advancing Next Generation T cell Engagers for Solid Tumor Treatments Yonglei Shang, MD, MS, CTO, Amberstone Biosciences
11:10-11:45 am

Unleashing Immune Tolerance: The Story of LAPIX Therapeutics from Idea to Clinic

Anas Fathallah, PhD, Co-Founder and CEO, LAPIX Therapeutics
11:45 am -12:15 pm Panel Discussion, Q&A and Symposium Conclusion All Speakers

Catherine Sabatos-Peyton, Ph.D., is Larkspur Bioscience’s Chief Executive Officer. Most recently Executive Director, Head of Immune Modulation at the Novartis Institutes for BioMedical Research (NIBR), Catherine spent 7 years building the team focused on biologics and small molecule drug development programs. Previously, while at the biotech CoStim, Catherine led the discovery of the first-in-class anti-TIM-3 antibody, sabatolimab, and then oversaw its advancement to Phase 2/3 studies in acute myeloid leukemia and myelodysplastic syndrome at NIBR. After embarking on autoimmunity research during a Fulbright Fellowship at Oxford, Catherine received her Ph.D. in Immunology from Harvard University.

Cyriac  is a serial entrepreneur on the intersection of the physical and the digital worlds, who loves challenging missions that move the world forward. Earli is his fourth startup, and his first one in TechBio. His prior startup was acquired for $250M, an 11x return for the lead investor (Kleiner Perkins). Through his family office Roeding Ventures, he has invested directly in 20 startups in Silicon Valley (including OpenAI), India and Europe, and in some of the world’s leading venture capital funds, including a16z, Founders Fund, Bond, Greylock, IVP, Breakthrough Ventures. He incubated  Shopkick  in the basement of Kleiner Perkins during the financial crisis, a shopping app that rewards consumers just for walking into stores without having to buy anything. Before that, he created CBS Television’s mobile division in Los Angeles, and co-founded 12snap in Europe, one of the first mobile marketing firms, working with Coca-Cola, McDonald’s, Sony Playstation and others. Cyriac sold his first computer program in Germany at age 15, attended high school in Texas where he proudly ran the school flag at Friday night football games, and studied Japanese Management in Tokyo. At 25, he co-authored the Harvard Business School book Secrets of Software Success while at McKinsey, where he devised growth strategies for global software and media firms. He was named a World Economic Forum Tech Pioneer, a Fortune 40 Under 40 Mobilizer, and subsequently, a World Economic Forum Global Innovator. He is also actively promoting innovation plans for his original home country Germany. Today, he has three beloved mini children who push him and his startup-loving wife Angel to the outermost frontier in multitasking.

Brad Niles, Ph.D. serves as the CEO for ARIZ Precision Medicine. He received his Ph.D. from UC Davis, with a Designated Emphasis in Biotechnology and advanced training in Business Development. He has 15 years of experience in cancer research, and has published more than a dozen scientific papers, and was an invited speaker to numerous scientific conferences. In addition, he has managed product development projects for two different biotech startups, and is an inventor on numerous RNA-therapeutic patent applications. At ARIZ he has previously served as COO and VP of Research and Development for over 4 years.


2025-02-26, [In-Person] Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
2025-04-01, [For vendors ONLY] Seattle PBSS Seminar Luncheon Vendor Show
2025-04-09, [In-Person] Cell Therapy Discovery and Development: Fundamentals, Strategies and Best Practices (jointly by PBSS and RAPS-SF)
2025-04-22, [Free Online Workshop] Career Transitions for Research Scientists: BD/Sales in CROs, CDMOs, and Lab Products & Instruments
2025-04-25, [In-Person] Drug Metabolism Fundamentals and Metabolite Identification
2025-05-05, [Free Online] Highlights of 2024 FDA Drug Approvals
2025-05-12, [In-Person] Preclinical Pharmacology Studies and Translational Medicine for Drug Discovery and Development
2025-06-02, [In-Person] Metabolism and Transport-mediated Drug-Drug Interaction: Current Practices, Regulatory Guidances, and Their Impact on Drug Development
©Pharmaceutical & BioScience Society, International; Last Modified: 2/12/2025; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Allucent Experts bringing development innovation w/ClinPharm Modeling & Simulation deliverables to inform dose, study design, modeling+development strategies.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Submit a Text Ad